Contrave's Fate to be Decided by FDA Panel Dec 7

Contrave™ will have it's day on Tuesday, December 7 when an FDA panel of experts vote to approve it or send it back to the drawing board. The Food & Drug Administration released information on Friday sending mixed signals about Contrave™. The drug definitely helped users lose weight, but may not have reached the required FDA standards.

The FDA information also raised questions about potential side effects. Since two other weight loss drugs (Qnexa™and Lorcaserin™) failed to gain approval from the FDA panel of experts earlier this year and were not approved for use by the FDA, many experts are not too optimistic on Contrave™'s chances.

Here is a link to the FDA's recently published information on Contrave™ for the upcoming panel meeting. Orexigen Briefing Information for the December 7, 2010 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee

Technorati Tags: Contrave™ naltrexone Diet Pills Weight Loss Pillsbupropion Diet Weight Loss Losing Weight